Published on 5 Jan 2024 on Simply Wall St. via Yahoo Finance
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 221% Above Its Share Price
Key Insights
Myriad Genetics' estimated fair value is US$57.52 based on 2 Stage Free Cash Flow to EquityMyriad Genetics is estimated to be 69% undervalued based on current share price of US$17.91Our fair value estimate is 160% higher than Myriad Genetics' analyst price target of US$22.08
Does the January share price for Myriad Genetics, Inc. (NASDAQ:MYGN) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. Believe it or not, it's not too difficult to follow, as you'll see from our example!